Categories AlphaGraphs, Earnings, Technology

Keysight Technologies stock gains as Q3 earnings, revenue beat

Keysight Technologies, Inc. (NYSE: KEYS), a provider of test and measurement equipment, reported lower earnings and revenues for the third quarter of 2020. The results, however, topped expectations and the company’s stock gained on Thursday evening.

Keysight Technologies Q3 Earnings Infographic

Third-quarter revenues were $1.01 billion, down 7% from last year but sharply above the consensus forecast.

Adjusted earnings, excluding one-off items, dropped to $1.19 per share from $1.25 per share in the prior-year quarter. Net income came in at $176 million or $0.93 per share, compared to $159 million or $0.83 per share in the third quarter of 2019. Analysts had predicted a lower bottom-line number.


Looking forward to listening to management/analysts’ comments on Q3 results? Stay tuned here for Keysight’s Q3 2020 earnings call transcript 


After a series of ups and downs, Keysight’s stock is currently trading broadly at the levels seen at the beginning of the year. It closed Thursday’s trading down 1% but moved up during the extended session soon after the earnings announcement.

Most Popular

WMT Earnings: All you need to know about Walmart’s Q2 2023 earnings results

Walmart Inc. (NYSE: WMT) reported second quarter 2023 earnings results today. Total revenue increased 8.4% year-over-year to $152.9 billion. Revenues grew 9.1% in constant currency. Consolidated net income attributable to

Rivian (RIVN) reaffirms production goals. Will it be a smooth ride?

The evolution of the electric vehicle industry accelerated in recent years even as innovations in battery technology and affordability brought EVs into the mainstream. Encouraged by the success of market

Pfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term

Shares of Pfizer Inc. (NYSE: PFE) were down on Monday. The stock has dropped 15% year-to-date and there is a mixed sentiment surrounding the company’s growth prospects. Pfizer has benefited

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top